Phenobarbital-induced increase of the hexose 6-phosphate dehydrogenase activity

Expression of hexose-6-phosphate dehydrogenase in rat tissues

Hexose-6-phosphate dehydrogenase (H6PD) is the main NADPH generating enzyme in the lumen of the endoplasmic reticulum. H6PD is regarded as an ancillary enzyme in prereceptorial glucocorticoid activation and probably acts as a nutrient sensor and as a prosurvival factor. H6PD expression was determined in a variety of rat and human tissues by detecting mRNA and protein levels, and by measuring its dehydrogenase and lactonase activities. It was found that H6PD was present in all investigated tissues; both expression and activity remained within an order of magnitude. Correlation was found between the dehydrogenase activity and protein or mRNA levels. The results confirmed the supposed housekeeping feature of the enzyme.

Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum

Hexose-6-phosphate dehydrogenase (H6PD) is a luminal enzyme of the endoplasmic reticulum that is distinguished from cytosolic glucose-6-phosphate dehydrogenase by several features. H6PD converts glucose-6-phosphate and NADP(+) to 6-phosphogluconate and NADPH, thereby catalyzing the first two reactions of the pentose-phosphate pathway. Because the endoplasmic reticulum has a separate pyridine nucleotide pool, H6PD provides NADPH for luminal reductases. One of these enzymes, 11beta-hydroxysteroid dehydrogenase type 1 responsible for prereceptorial activation of glucocorticoids, has been the focus of much attention as a probable factor in the pathomechanism of several human diseases including insulin resistance and the metabolic syndrome. This review summarizes recent advances related to the functions of H6PD.

Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1

Intracellular glucocorticoid reactivation is catalyzed by 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1), which functions predominantly as a reductase in cells expressing hexose-6-phosphate dehydrogenase (H6PDH). We recently showed that the ratios of cortisone to cortisol and 7-keto- to 7-hydroxy-neurosteroids are regulated by 11beta-HSD1 and very much depend on coexpression with H6PDH, providing cosubstrate NADPH. Here, we investigated the impact of H6PDH on the modulation of 11beta-HSD1-dependent interconversion of cortisone and cortisol by inhibitors and alternative substrates. Using HEK-293 cells expressing 11beta-HSD1 or coexpressing 11beta-HSD1 and H6PDH, we observed significant differences of 11beta-HSD1 inhibition by natural and pharmaceutical compounds as well as endogenous hormone metabolites. Furthermore, we show potent and dose-dependent inhibition of 11beta-HSD1 by 7-keto-DHEA in differentiated human THP-1 macrophages and in HEK-293 cells overexpressing 11beta-HSD1 with or without H6PDH. In contrast, 7-ketocholesterol (7-KC) did not inhibit 11beta-HSD1 in HEK-293 cells, even in the presence of H6PDH, but inhibited 11beta-HSD1 reductase activity in differentiated THP-1 macrophages (IC(50) 8.1+/-0.9microM). 7-Keto-DHEA but not 7-KC inhibited 11beta-HSD1 in HEK-293 cell lysates. In conclusion, cellular factors such as H6PDH can significantly modulate the effect of inhibitors and alternative 7-oxygenated substrates on intracellular glucocorticoid availability.

Hexose-6-phosphate dehydrogenase and 11beta-hydroxysteroid dehydrogenase-1 tissue distribution in the rat

Intracellular concentrations of the glucocorticoids cortisol and corticosterone are modulated by the enzymes 11beta-hydroxysteroid dehydrogenase (11beta-HSD) 1 and 2. 11beta-HSD1 is a reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent microsomal reductase that converts the inactive glucocorticoids cortisone and 11-dehydrocorticosterone to their active forms, cortisol and corticosterone. Hexose-6-phosphate dehydrogenase (H6PDH) is an enzyme that generates NADPH from oxidized NADP (NADP(+)) within the endoplasmic reticulum. In the absence of NADPH or H6PDH to regenerate NADPH, 11beta-HSD1 acts as a dehydrogenase and inactivates glucocorticoids, as does 11beta-HSD2. A monoclonal antibody against H6PDH was produced to study the possibility that 11beta-HSD1 in the absence of H6PDH may be responsible for hydroxysteroid dehydrogenase activity in tissues that do not express significant amounts of 11beta-HSD2. H6PDH and 11beta-HSD1 expression was surveyed in a variety of rat tissues by real-time RT-PCR, Western blot analysis, and immunohistochemistry. H6PDH was found in a wide variety of tissues, with the greatest concentrations in the liver, kidney, and Leydig cells. Although the brain as a whole did not express significant amounts of H6PDH, some neurons were clearly immunoreactive by immunohistochemistry. H6PDH was amply expressed in most tissues examined in which 11beta-HSD1 was also expressed, with the notable exception of the renal interstitial cells, in which dehydrogenase activity by 11beta-HSD1 probably moderates activation of the glucocorticoid receptor because rat renal interstitial cells do not have significant amounts of mineralocorticoid receptors. This antibody against the H6PDH should prove useful for further studies of enzyme activity requiring NADPH generation within the endoplasmic reticulum.

Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity

Hexose-6-phosphate dehydrogenase (H6PDH) is a microsomal enzyme that is able to catalyze the first two reactions of an endoluminal pentose phosphate pathway, thereby generating reduced nicotinamide adenine dinucleotide phosphate (NADPH) within the endoplasmic reticulum. It is distinct from the cytosolic enzyme, glucose-6-phosphate dehydrogenase (G6PDH), using a separate pool of NAD(P)+ and capable of oxidizing several phosphorylated hexoses. It has been proposed to be a NADPH regenerating system for steroid hormone and drug metabolism, specifically in determining the set point of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity, the enzyme responsible for the activation and inactivation of glucocorticoids. 11beta-HSD1 is a bidirectional enzyme, but in intact cells displays predominately oxo-reductase activity, a reaction requiring NADPH and leading to activation of glucocorticoids. However, in cellular homogenates or in purified preparations, 11beta-HSD1 is exclusively a dehydrogenase. Because H6PDH and 11beta-HSD1 are coexpressed in the inner microsomal compartment of cells, we hypothesized that H6PDH may provide 11beta-HSD1 with NADPH, thus promoting oxo-reductase activity in vivo. Recently, several studies have confirmed this functional cooperation, indicating the importance of intracellular redox mechanisms for the prereceptor control of glucocorticoid availability. With the increased interest in 11beta-HSD1 oxo-reductase activity in the pathogenesis and treatment of several human diseases including insulin resistance and the metabolic syndrome, H6PDH represents an additional novel candidate for intervention.

Glucose dehydrogenase in teleosts: tissue distribution and proposed function

Tissue extracts of skeletal muscle, heart, eye, brain, liver, kidney, gill and stomach were electrophoretically examined for glucose dehydrogenase (EC 1.1.1.47) activity in 21 species of marine teleost fishes. Glucose dehydrogenase expression was detected only in liver extracts. Considerable interordinal variation was found in levels of enzymatic activity. Available data support the hypothesis that glucose dehydrogenase provides NADPH for the mixed-function oxidase system in teleosts.

Evidence for the homology of hexose 6-phosphate dehydrogenase and glucose 6-phosphate dehydrogenase: comparison of the amino acid compositions

Amino acid compositions of hexose 6-phosphate dehydrogenase and glucose 6-phosphate dehydrogenase from crucian carp and rat, and that of sea-urchin glucose 6-phosphate dehydrogenase were compared in order to ascertain if they are homologous enzymes. The results demonstrated that the overall amino acid compositions of the two enzymes remarkably resemble each other, and that the composition divergence (D = 0.038) of the crucian carp enzymes is in the range of those for homologous proteins so far reported. These findings strongly support our previous prediction that the two enzymes have diverged from a common ancestral molecule.

Differential effects of the NADPH/NADP+ ratio on the activities of hexose-6-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase

The steady-state kinetics of rat liver hexose-6-phosphate dehydrogenase (beta-D-glucose: NAD(P)+ 1-oxidoreductase, EC 1.1.1.47) using glucose 6-phosphate and NADP+ as substrates is studied. NADPH has been found to inhibit the enzyme noncompetitively with respect to NADP+, and uncompetitively with respect to glucose 6-phosphate. At a given concentration of glucose 6-phosphate, the reaction follows the basic inhibition equation. This suggests the presence of the enzyme-NADP+-NADPH complex, and contrasts with the NADPH inhibition of glucose-6-phosphate dehydrogenase which is competitive with respect to NADP+. An attempt was made to estimate the in vivo activities of the two enzymes in rat liver in the presence of NADPH at various NADPH/NADP+ ratios. The results show that the two enzymes appear to be at about the same level of activity in normal rat liver where the coenzyme redox ratio is 110 and the glucose 6-phosphate concentration is 217 microM. Under the same conditions, but with 50 microM dehydroepiandrosterone, a potent inhibitor of glucose-6-phosphate dehydrogenase, but not of hexose-6-phosphate dehydrogenase, the latter enzyme is estimated to be 1.6-times as active as the former. Such differential effects of NADPH and steroids on the two enzymes may support our notion that hexose-6-phosphate dehydrogenase may have advantages over glucose-6-phosphate dehydrogenase (D-glucose-6-phosphate: NADP+ 1-oxidoreductase, EC 1.1.1.49) in steroid-metabolizing tissues (the activity of hexose-6-phosphate dehydrogenase is not, or less, affected by steroids of NADPH).

Alterations in the latency of hepatic microsomal hexose-6-phosphate dehydrogenase under various in vivo and in vitro conditions

To gain insight into the cause of the latency of microsomal hexose-6-phosphate dehydrogenase activity, changes in the activity and latency of hexose-6-phosphate dehydrogenase were examined to determine whether they were parallel to those of other microsomal enzymes (UDP glucuronyltransferase, nucleoside diphosphatase and glucose-6-phosphatase) during development and after treatments of rats with phenobarbital and a high carbohydrate diet. We also examined whether the latency of hexose-6-phosphate dehydrogenase could be ascribed to changes in the cholesterol content and phospholipid composition of microsomes under various conditions. The results show that the activities and latencies of the four microsomal enzymes change independently during development and after various treatments, and that the phospholipid composition of microsomes does not have any direct effect on the latency of hexose-6-phosphate dehydrogenase.

Ecdysterone biosynthesis: a microsomal cytochrome-P-450-linked ecdysone 20-monooxygenase from tissues of the African migratory locust

Ecdysone 20-monooxygenase, an enzyme which converts ecdysone to ecdysterone (the major moulting hormone of insects) has been characterized in cell-free preparations of tissues from African migratory locust. The product of the reaction has been identified as ecdysterone on the basis of several microchemical derivatization and chromatographic methods. Ecdysone 20-monooxygenase activity is located primarily in the microsomal fraction which also carries NADPH cytochrome c reductase and cytochrome P-450, as shown by sucrose density gradient centrifugation. Optimal conditions for the ecdysone 20-monooxygenase assay have been determined. The enzyme has a Km for ecdysone of 2.7 x 10(-7) M and is competitvely inhibited by ecdysterone (Ki = 7.5 x 10(-7) M). Ecdysone 20-monooxygenase is a typical cytochrome P-450 linked monooxygenase: the reaction requires O2 and is inhibited by CO, an effect partially reversed by white light. The enzyme is effectively inhibited by several specific monooxygenase inhibitors and by sulfhydryl reagents, but not by cyanide ions. Ecdysone elicits a type I difference spectrum when added to oxidized microsomes. NADPH acts as preferential electron donor. The transfer of reducing equivalents proceeds through NADPH cytochrome c (P-450) reductase: ecdysone 20-monooxygenase is inhibited by cytochrome c. Both NADPH cytochrome c reductase and ecdysone 20-monooxygenase are inhibited by NADP+ and show a similar Km for NADPH. The Malpighian tubules have the highest specific activity of ecdysone 20-monooxygenase, while fat body contain most of the cytochrome P-450 and NADPH cytochrome c reductase.

Intramembraneous localization of rat liver microsomal hexose-6-phosphate dehydrogenase and membrane permeability to its substrates

A method for purifying hexose-6-phosphate dehydrogenase (beta-D-glucose: NAD(P) -oxidoreductase, EC 1.1.1.47) from rat liver microsomes is described. The purified enzyme was shown to be homogeneous by sodium dodecyl sulfate (SDS)-polyacrylamide electrophoresis. It is shown that the enzyme is bound to the inner surface of microsomal membranes, and that glucose 6-phosphate, but not NADP, penetrates almost freely into the membranes at 37 degrees C.

The effect of phenobarbitone on cytoplasmic NADP-linked dehydrogenase activities in rat liver

Phenobarbitone administered in drinking water (0.5 g/l) or by daily intraperitoneal injection (100 mg/kg body weight) consistently caused an elevation of hepatic NADP-linked malic enzyme in rats maintained on a pellet diet. Three to four days appeared to be required for maximum response. The effect was also observed in animals maintained on a protein rich diet, in which the basic hepatic malic enzyme activity was low, but not in animals maintained on a sucrose rich diet, in which the basic enzyme activity was almost twice normal. Methyl cholanthrene, administered by daily intraperitoneal injection (40 mg/kg body weight), resulted in elevated hepatic levels not only of malic enzyme but also of the pentose phosphate pathway dehydrogenases. The timing of the "starve-refeed" response of the hepatic NADP-linked dehydrogenases in phenobarbitone-treated rats was similar to that in controls, and similar maximum enzyme activities were reached. The role of cytoplasmic NADP-linked dehydrogenases in the provision of reducing equivalent is discussed, particularly in relation to hepatic microsomal drug metabolism.

Latency of microsomal hexose-6-phosphate dehydrogenase activity

Intact microsomes isolated from rat liver showed no hexose-6-phosphate dehydrogenase activity, but the enzyme was activated by Triton X-100, deoxycholate, NH4OH, glycine/NaOH, lysophosphatidylcholine, phospholipases A and C, pancreatic lipase and cholesterol esterase, and also by sonic treatment. The enzyme activation by deoxycholate, NH4OH and sonic treatments was solely due to solubilization, while that by phospholipase A appeared to be due to the detergent action of the hydrolysis products. On the other hand, the primary effects of phospholipase C, cholesterol esterase and pancreatic lipase might be accounted for by the partial removal of membrane lipids. The results of washing and trypsin digestion experiments suggested that hexose-6-phosphate dehydrogenase is one of the most firmly bound enzymes among the microsomal proteins. The catalytic properties were the same in the solubilized and the membrane-bound, activated enzymes. Feeding the rats on a high carbohydrate diet altered the extent of enzyme activation by sonication and phospholipase C treatment, suggesting that the microsomal membrane would actually undergo changes in the conformation and/or chemical composition under certain circumstances.